Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future.
作者信息
Wang Ting-Yao, George Jacob, Zheng Ming-Hua
机构信息
Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia.
出版信息
Hepatobiliary Surg Nutr. 2021 Dec;10(6):849-852. doi: 10.21037/hbsn-21-352.
Abstract
摘要
相似文献
1
Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future.代谢（功能障碍）相关脂肪性肝病：更多证据与光明前景
Hepatobiliary Surg Nutr. 2021 Dec;10(6):849-852. doi: 10.21037/hbsn-21-352.
2
Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease.首字母缩略词从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的转变。
World J Hepatol. 2021 Oct 27;13(10):1203-1207. doi: 10.4254/wjh.v13.i10.1203.
3
Bright liver, body composition and insulin resistance changes with nutritional intervention: a follow-up study.营养干预对肝脏、身体成分及胰岛素抵抗的影响：一项随访研究
Liver Int. 2008 Nov;28(9):1280-7. doi: 10.1111/j.1478-3231.2008.01742.x. Epub 2008 Apr 23.
4
Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).药理治疗学：代谢功能障碍相关脂肪性肝病（MAFLD）的当前趋势
J Clin Transl Hepatol. 2021 Dec 28;9(6):939-946. doi: 10.14218/JCTH.2021.00189. Epub 2021 Jul 28.
5
Fatty liver and the metabolic syndrome among Shanghai adults.上海成年人中的脂肪肝与代谢综合征
J Gastroenterol Hepatol. 2005 Dec;20(12):1825-32. doi: 10.1111/j.1440-1746.2005.04058.x.
6
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.将脂肪肝纳入代谢性疾病患者的多学科治疗和新型临床试验设计中。
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):743-753. doi: 10.1016/S2468-1253(21)00132-1. Epub 2021 Jul 12.
7
Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.非酒精性脂肪性肝病是代谢健康人群代谢性疾病的早期预测指标。
PLoS One. 2019 Nov 4;14(11):e0224626. doi: 10.1371/journal.pone.0224626. eCollection 2019.
8
The relationship between pancreas steatosis and the risk of metabolic syndrome and insulin resistance in Chinese adolescents with concurrent obesity and non-alcoholic fatty liver disease.中国同时患有肥胖症和非酒精性脂肪肝的青少年中，胰腺脂肪变性与代谢综合征和胰岛素抵抗风险的关系。
Pediatr Obes. 2020 Sep;15(9):e12653. doi: 10.1111/ijpo.12653. Epub 2020 Apr 29.
9
Nonalcoholic Fatty Liver Disease, Male Sexual Dysfunction, and Infertility: Common Links, Common Problems.非酒精性脂肪性肝病、男性性功能障碍与不育症：共同关联、共同问题
Sex Med Rev. 2020 Apr;8(2):274-285. doi: 10.1016/j.sxmr.2019.01.002. Epub 2019 Mar 19.
10
Non-alcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: Conceptual changes for clinicians, researchers and patients.非酒精性脂肪性肝病向代谢相关脂肪性肝病的转变：对临床医生、研究人员和患者的概念改变。
J Dig Dis. 2020 Nov;21(11):604-609. doi: 10.1111/1751-2980.12944. Epub 2020 Nov 2.
引用本文的文献
1
Predictive Value of the Chinese Visceral Adiposity Index for Metabolic Dysfunction-Associated Fatty Liver Disease and Elevated Alanine Aminotransferase Levels in Nonobese Chinese Adults: A Cross-Sectional Study.中国内脏脂肪素指数对非肥胖中国成年人代谢功能障碍相关脂肪性肝病及丙氨酸氨基转移酶水平升高的预测价值：一项横断面研究
J Inflamm Res. 2024 Jun 18;17:3893-3913. doi: 10.2147/JIR.S468093. eCollection 2024.
2
Association between Serum Ferritin Levels and Metabolic-associated Fatty Liver Disease in Adults: a Cross-sectional Study Based on the NHANES.血清铁蛋白水平与成年人代谢相关脂肪性肝病的相关性：基于 NHANES 的横断面研究。
Curr Med Sci. 2024 Jun;44(3):494-502. doi: 10.1007/s11596-024-2868-0. Epub 2024 May 15.
3
An international multidisciplinary consensus statement on MAFLD and the risk of CVD.国际多学科共识声明：MAFLD 和 CVD 风险。
Hepatol Int. 2023 Aug;17(4):773-791. doi: 10.1007/s12072-023-10543-8. Epub 2023 May 19.
4
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.代谢相关脂肪性肝病与心血管风险及疾病预防。
Cardiovasc Diabetol. 2022 Dec 3;21(1):270. doi: 10.1186/s12933-022-01697-0.
5
Surgical treatment of secondary hyperparathyroidism combined with Sagliker syndrome caused by chronic renal failure: a case report.慢性肾衰竭所致继发性甲状旁腺功能亢进合并萨利克综合征的外科治疗：1例报告
Gland Surg. 2022 Sep;11(9):1568-1573. doi: 10.21037/gs-22-479.
6
Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.新旧降糖药物治疗非酒精性脂肪性肝病：叙述性综述。
Clin Mol Hepatol. 2022 Oct;28(4):725-738. doi: 10.3350/cmh.2022.0015. Epub 2022 Mar 14.
7
Association of metabolic dysfunction-associated fatty liver disease with kidney disease.代谢功能障碍相关脂肪性肝病与肾脏疾病的关联
Nat Rev Nephrol. 2022 Apr;18(4):259-268. doi: 10.1038/s41581-021-00519-y. Epub 2022 Jan 10.
本文引用的文献
1
NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III.非酒精性脂肪性肝病（NAFLD）还是代谢功能障碍相关脂肪性肝病（MAFLD）：哪种与全因死亡率和特定病因死亡率的关联更紧密？——来自美国国家健康和营养检查调查（NHANES）III的结果
Front Med (Lausanne). 2021 Jul 1;8:693507. doi: 10.3389/fmed.2021.693507. eCollection 2021.
2
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.将脂肪肝纳入代谢性疾病患者的多学科治疗和新型临床试验设计中。
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):743-753. doi: 10.1016/S2468-1253(21)00132-1. Epub 2021 Jul 12.
3
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.非酒精性脂肪性肝病和/或代谢相关脂肪性肝病患者的临床特征差异及死亡结局。
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2172-2181.e6. doi: 10.1016/j.cgh.2021.05.029. Epub 2021 May 23.
4
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.中华医学会肝病学分会关于脂肪肝疾病重新定义的立场声明。
J Hepatol. 2021 Aug;75(2):454-461. doi: 10.1016/j.jhep.2021.05.003. Epub 2021 May 19.
5
Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.估算超重或肥胖成年人代谢功能障碍相关脂肪性肝病的全球患病率。
Clin Gastroenterol Hepatol. 2022 Mar;20(3):e573-e582. doi: 10.1016/j.cgh.2021.02.030. Epub 2021 Feb 20.
6
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population.当代美国人群中 NAFLD、MAFLD 和相关晚期纤维化的患病率。
Liver Int. 2021 Jun;41(6):1290-1293. doi: 10.1111/liv.14828. Epub 2021 Mar 3.
7
Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.从非酒精性脂肪性肝病（NAFLD）到代谢功能障碍相关脂肪性肝病（MAFLD）的转变提高了基层医疗医生和专科医生对脂肪性肝病的认识。
J Hepatol. 2021 May;74(5):1254-1256. doi: 10.1016/j.jhep.2020.12.035. Epub 2021 Feb 11.
8
Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.非酒精性脂肪性肝病和代谢相关脂肪性肝病的结局：一项基于社区的前瞻性队列研究结果。
PLoS One. 2021 Feb 3;16(2):e0245762. doi: 10.1371/journal.pone.0245762. eCollection 2021.
9
The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.撒哈拉以南非洲关于脂肪肝疾病重新定义的立场声明：从非酒精性脂肪性肝病到代谢相关脂肪性肝病
J Hepatol. 2021 May;74(5):1256-1258. doi: 10.1016/j.jhep.2021.01.015. Epub 2021 Jan 20.
10
From NAFLD to MAFLD: Nurse and allied health perspective.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：护士及相关健康专业人员的视角
Liver Int. 2021 Apr;41(4):683-691. doi: 10.1111/liv.14788. Epub 2021 Feb 2.
Zotero 插件